Our Services
Medical Information
Helpful Resources
Published on: 4/24/2026
Sulfur burps after starting Ozempic often stem from slowed gastric emptying and changes in gut bacteria, and while mild, infrequent burps typically improve with diet tweaks and time, persistent or intense burps accompanied by pain, vomiting, weight loss, or fever may be red flags.
Use the detailed checklist below to track timing, severity, and associated symptoms and to decide when to adjust your diet, consult your provider, or seek urgent care. Many important nuances and next steps can be found below.
Ozempic (semaglutide) is a GLP-1 receptor agonist approved for type 2 diabetes management and, more recently, for weight loss. While many users benefit from better blood sugar control and reduced appetite, gastrointestinal side effects can occur. One bothersome complaint is "Ozempic sulfur burps." If you've noticed sulfur-smelling belches after starting Ozempic, here's a clear checklist to help you decide when it's routine and when it might be a red flag.
Sulfur burps (also called "rotten egg burps") are belches that smell strongly of hydrogen sulfide gas. Common causes include:
In most cases, sulfur burps are more of an annoyance than a danger. But with Ozempic, they can indicate how your body is adapting—or, rarely, a complication requiring medical attention.
Ozempic works by:
Slower emptying means food and stomach acid remain longer in the stomach and small intestine. This can:
For most, these effects ease within a few weeks as the body adapts. If sulfur burps persist or worsen, use the checklist below to decide if you need further evaluation.
Use this guide to track your symptoms. Check off any that apply:
If your burps are mild, infrequent, and improve with simple measures, they're probably not a red flag. Try:
Track your progress: if burps ease within 2–4 weeks of starting Ozempic or adjusting diet, you can likely continue current management.
Some signs suggest you should take sulfur burps more seriously. Seek medical advice if you experience:
These symptoms could indicate complications such as:
Keep a Symptom Journal
Adjust Diet & Habits
Use an Online Symptom Checker
If you're experiencing these symptoms and want personalized guidance on whether to seek care, try this Medically approved LLM Symptom Checker Chat Bot to get a detailed assessment based on your specific situation in minutes.
Consult Your Healthcare Provider
Many people benefit from continuing Ozempic despite mild GI side effects. If your burps are manageable:
Always check with your doctor before adding supplements or making major dietary shifts.
Go to the nearest ER or call emergency services if you have:
These could signal life-threatening conditions like acute pancreatitis or gastrointestinal bleeding.
Sulfur burps after starting Ozempic are a common GI side effect due to slowed gastric emptying and changes in gut bacteria. For most, simple diet tweaks and time help. Use the checklist above to monitor timing, severity, and associated symptoms. If you face red-flag signs—severe pain, vomiting, weight loss, fever—seek medical care without delay.
If you're uncertain about your symptoms or need help determining your next steps, consider using this Medically approved LLM Symptom Checker Chat Bot for a quick, free assessment tailored to your concerns. And always speak to a doctor about any new, severe, or life-threatening symptoms.
Your healthcare provider can tailor a plan so you safely benefit from Ozempic while keeping GI side effects under control.
(References)
* Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, 384(11), 989-1002.
* Blonde, L., & Blonde, C. M. (2021). Semaglutide in type 2 diabetes and obesity: a review of the current evidence. Drugs of Today (Barcelona, Spain: 1998), 57(12), 655-668.
* Ahrén, B., Andreassen, M., Sjøstrøm, C. D., et al. (2022). Gastrointestinal adverse events with once-weekly semaglutide 2.4 mg in patients with overweight or obesity: A pooled analysis. Diabetes, Obesity and Metabolism, 24(7), 1335-1345.
* Smits, M. M., & Van Raalte, D. H. (2021). Safety of Semaglutide. Frontiers in Endocrinology, 12, 645564.
* Lee, C. J., & Tan, T. (2023). GLP-1 Receptor Agonists and Gastroparesis: A Review of Current Evidence and Clinical Implications. Clinical Diabetes and Endocrinology, 9(1), 18.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.